Abstract
This study was designed to investigate the role of serum GP73 for diagnosing significant fibrosis in patients with chronic hepatitis B virus (HBV) infections. Two populations were enrolled. All subjects were patients with chronic HBV infections. The first population included 761 patients who received liver stiffness measurement; the second population included 633 patients who underwent liver biopsy, including 472 patients with nearly normal ALT. All patients received serum GP73 tests. The effect of GP73 recombinant protein on HepG2 cells and LX2 cells was observed in vitro. Results showed that serum GP73 concentration is correlated with liver stiffness (r = 0.601). The area under the ROC curve is 0.76. The sensitivity and specificity of GP73 for significant fibrosis (≥F2) diagnosis were 62.81% and 80.05% respectively (cut-off: 76.6 ng/ml). GP73 had a striking performance for diagnosing S2 in patients with chronic HBV infections, even in those with nearly normal ALT. GP73 recombinant protein may prompt LX2 cell proliferation at concentrations of 10-100 ng/ml. These results indicate that GP73 may be a marker for diagnosing significant fibrosis and a new contributor to fibrogenesis.
Introduction: The Challenge of Silent Fibrosis
Chronic HBV infection remains a global health challenge, often progressing to hepatic fibrosis—the accumulation of scar tissue—and eventually cirrhosis or hepatocellular carcinoma. The current "gold standard" for assessment is liver biopsy, which is invasive and prone to sampling errors. While non-invasive tools like transient elastography (FibroScan) are available, they have limitations, particularly in identifying "silent" progression in patients with nearly normal Alanine Aminotransferase (ALT) levels. This study explores whether serum GP73, a Golgi-specific protein, can serve as a reliable non-invasive biomarker for these at-risk populations.
Methods and Datasets
The researchers utilized a dual-track approach involving 1,394 patients from Beijing Ditan Hospital and 302 Military Hospital:
- Clinical Cohorts:
- Cohort A (n=761): Evaluated for correlation between serum GP73 and physical liver stiffness.
- Cohort B (n=633): Evaluated via histological biopsy, with a sub-focus on 472 patients with nearly normal ALT levels.
- Biochemical and Mechanistic Studies: Serum GP73 levels were measured via ELISA. In vitro experiments used HepG2 and LX2 (hepatic stellate) cell lines to determine if GP73 actively influences cell proliferation and collagen production.
Key Insights: GP73 as a Dynamic Mediator
A critical finding of this research is that GP73 is likely more than a passive marker; it appears to be an active mediator of the disease. The study observed a clear, stepwise increase in GP73 levels corresponding to the severity of liver stiffness.
Furthermore, the mechanistic study found that recombinant GP73 prompted LX2 cells—the primary drivers of liver scarring—to multiply and up-regulate Collagen III expression. This suggests that GP73 may catch "stealth" fibrosis that standard ALT screenings miss because it is biologically linked to the fibrotic process itself.
Results: Diagnostic Performance
The clinical data confirmed a strong positive correlation between serum GP73 and liver stiffness ($r = 0.601$).
Key performance metrics included:
- Significant Fibrosis (≥F2): GP73 achieved a sensitivity of 62.81% and specificity of 80.05% (cut-off: 76.6 ng/ml; AUROC = 0.76).
- Cirrhosis Detection (F4): The marker showed even higher accuracy for cirrhosis, with an AUROC of 0.88.
- Normal ALT Subgroup: In the 472 patients with nearly normal ALT, GP73 maintained a sensitivity of 62.5% and specificity of 80.0% for identifying significant fibrosis (S2).
Discussion and Limitations
While serum GP73 demonstrates significant potential as a non-invasive diagnostic tool, the authors acknowledge limitations. Some advanced fibrosis subgroups were smaller, which may affect statistical variance. Additionally, the exact molecular signaling pathways through which GP73 stimulates LX2 cells remain a "pendent question." Future work should include head-to-head comparisons with other established multi-marker panels like FibroTest. Ultimately, targeting GP73 could provide a novel therapeutic strategy to slow or reverse liver fibrogenesis.
Summary updated